Bococizumab

Bococizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Clinical data
Routes of
administration
Subcutaneous injection
ATC code none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 1407495-02-6
PubChem (SID) 194168554
IUPHAR/BPS 7730
ChemSpider none
ChEMBL CHEMBL3137349
Chemical and physical data
Formula C6414H9918N1722O2012S54
Molar mass 145.1 kg/mol

Bococizumab (USAN;[1] development code RN316[2]) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol.[3] Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."[4]

Description

Bococizumab is a monoclonal antibody that inhibits PCSK9, a protein that interferes with the removal of LDL. LDL levels are a major risk factor for cardiovascular disease.[5]

Clinical trials

A phase 2b study of statin patients was presented at the 2014 American College of Cardiology.[3] Monthly or bimonthly injections resulted in significantly reduced LDL-C at week 12.

The Phase 3 SPIRE trials plan to enroll 17,000 patients to measure cardiovascular risk. High risk and statin intolerant subjects will be included.

References


This article is issued from Wikipedia - version of the 11/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.